Home >Technologies available >Technologies available for licensing

RNA therapy for neurodegenerative, cardiac, and pulmonary disease

Image from Licence Details: RNA therapy for neurodegenerative, cardiac, and pulmonary disease

Applications: Therapeutics, RNA therapies, Neurodegenerative diseases

MEG3 is a long non-coding RNA, implicated in Neurodegenerative, cardiac, and pulmonary disease. In Alzheimer’s disease a knockdown model was shown to have reduced necroptosis. The technology is oligonucleotide-based therapies to target the transcript.

Features Benefits
  • Targets MEG3
  • Implicated in neurodegenerative, cardiac, and pulmonary disease
  • Can reduce MEG3 expression to 5% or lower
  • Optimise expression level
  • Efficacy in gapmer and siRNA formats
  • Multiple approaches to suit disease and technology
  • Reduces necroptosis
  • Targets main driver of AD pathology

Patented and available for:

  • Licensing
  • Co-development
  • Consulting
Request more information
about this technology

Back to Technologies Available

Sparks Background Image

Ready to get in touch?

Contact Us
Sparks Background Image
© Oxford University Innovation